AOI Gurugram Advances Precision Medicine for Rare Blood Disorders
Successful Treatment of Rare Blood Disorder with Targeted Approach
Delhi: In a significant step towards precision medicine, American Oncology Institute (AOI), Gurugram successfully treated a 65-year-old woman suffering from essential thrombocytosis, a rare hematological disorder. This remarkable case demonstrates the power of targeted treatment and advanced genetic testing in providing life-changing care.
The patient, a known case of hypertension, presented with persistent headaches and mild gum bleeding over four months. On examination, her blood pressure was high and further tests revealed a severely elevated platelet count exceeding 15 lakh per microliter of blood, alongside mild anemia. Advanced genetic tests identified a specific mutation, and the bone marrow biopsy confirmed the diagnosis of essential thrombocytosis, a rare condition with an annual incidence of just 1 to 2.5 per 100,000 people.
Harish Trivedi, CEO, CTSI-South Asia, emphasized, “AOI continues to set benchmarks in cancer and hematological care through its adoption of cutting-edge diagnostics and treatments. This case reflects our dedication to bringing world-class healthcare to every patient.”
Dr (Brig) A.K. Dhar, Medical Oncology, AOI Gurugram, explained, “Essential thrombocytosis is a diagnosis of exclusion, requiring detailed genetic and clinical studies to differentiate it from more common causes of high platelet counts. The treatment involves targeted cytoreductive therapy to lower platelet levels and prevent complications like clotting or bleeding.”
The patient was treated with hydroxyurea, an advanced cytoreductive medication, and antiplatelet agents. Within weeks, her platelet counts normalized, and she is now stable.
Highlighting AOI’s commitment to advanced care, Dr Amit Dhawan, Regional Chief Operating Officer (RCOO), AOI Gurugram, stated, “This case underscores the importance of precision medicine and our multidisciplinary approach in treating rare disorders. Our ability to leverage genetic insights ensures that patients receive accurate diagnoses and effective therapies tailored to their unique needs.”
Essential thrombocytosis is a rare blood disorder characterized by an excessive production of platelets, which can lead to clotting or bleeding issues. Diagnosis requires ruling out other causes, such as infections, iron deficiency, or malignancies, through comprehensive testing, including genetic studies and bone marrow examination.
Dr Dhar concluded, “This successful outcome highlights the vital role of timely diagnosis and advanced therapies in managing even the rarest conditions. At AOI, we are committed to helping patients lead healthier lives through precision medicine.”
